PAA—The Cell Culture Company - - BioPharm International

ADVERTISEMENT

PAA—The Cell Culture Company

BioPharm International
Volume 19, Issue 12

Company Description



PAA Laboratories, founded in February 1988, specializes in the manufacture and worldwide distribution of cell culture products for research, development, diagnostic and biopharmaceutical production. The company mantains high standards in its manufacturing processes. As an example, PAA Laboratories is licensed to produce and offer cell culture reagents for in vivo cell culture use.

The most advanced facility of its kind in Europe will help PAA to become a highly qualified supplier to all customers active in biologic vaccine and drug production, industrial in-vivo organ transplantation, tissue engineering and other critical fields.

Products and Services

PAA processes and manufactures animal and human sera, standard and cell line specific media for cell culture, serum and protein free media, biochemical reagents and growth supplements. We also supply Bovine Serum Albumin (BSA) of different grades and purity levels all used as vital nutrients in cell culture technology.



Our services also include the manufacturing of customized liquids and contract filling. The bottle, bag and container systems are single use and designed for the transport and storage of liquids for a wide range of applications.

The core competence of PAA is the sourcing and processing of animal serum. PAA manufacturers Foetal Bovine Serum in Europe. Due to the acquisition of GMP compliant manufacturing sites in North America and Australia we now serve a customer base world wide. For all serum products we do have the capability to supply batch sizes up to 2600 litres. Extensive documentation for full traceability (e.g. CoS, CoA, Veterinary Health Certificates, Batch Documentation) is available upon request.

Facilities

All our products are manufactured in three GMP facilities based in Austria, Australia and Canada.

In 2003 PAA Laboratories inaugurated a new, state-of-the-art, FDA registered, GMP-compliant manufacturing plant outside of Linz, Austria. This 5000 m3 pharmaceutical plant meets the most stringent US and European GMP regulations and is validated according to the ICH guideline of the manufacture of Active Pharmaceutical Ingredients (APIs).

In 2005 PAA acquired the GMP production facilities of Cansera, Canada. The facility is strategically located close to the Toronto International Airport and ideal for global distribution of serum and media products as well as ground and air transportation throughout North America.

The 20,000 sq. ft. facility is registered with FDA for production of sterile sera and media products for IVD use as well as contract production of sterile solutions. The North American facility that operates a completely segregated production suite for BSE free origin serum products. The facility and segregation is monitored by CFIA and has been subject to inspection and approval by USDA.

In Brisbane, Australia, PAA's operation includes integrated sourcing, collection, spinning and processing of raw bovine sera into finished sterile products. The production suite is fully compliant under GMP and has both CIP and SIP systems. Shipping of finished products directly from PAA Australia can be arranged.

PAA LABORATORIES
GmbH
+49.6421.175390

North America
PAA Laboratories Inc.
+1.508.984.5881

Australia
PAA Laboratories Ply Ltd
+61.738.993.941

WEB ADDRESS
http://www.paa.com/

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
Author Guidelines
Source: BioPharm International,
Click here